Welcome to Vectus Biosystems Limited

Vectus Biosystems Limited (ASX: VBS) is an Australian clinical-stage biotechnology company developing novel therapies for fibrotic diseases.

Today, Vectus is focused on advancing its lead compound VB0004 for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease with significant unmet medical need. VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models and has successfully completed Phase 1a clinical studies, establishing a favourable safety and pharmacokinetic profile.